Joseph Schoepfer
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Heat shock proteins research, Chemical Synthesis and Analysis, Protein Kinase Regulation and GTPase Signaling, Computational Drug Discovery Methods, Chronic Myeloid Leukemia Treatments
Most-Cited Works
- → The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1(2017)581 cited
- → Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1(2018)436 cited
- → Structural basis for specificity of GRB2-SH2 revealed by a novel ligand binding mode(1996)238 cited
- → NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models(2008)222 cited
- → Discovery of a Potent and Selective Protein Kinase CK2 Inhibitor by High-Throughput Docking(2003)215 cited
- → Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone(2009)173 cited
- → Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation(2019)173 cited
- → Inhibition of Cyclin-Dependent Kinase 4 (Cdk4) by Fascaplysin, a Marine Natural Product(2000)163 cited
- → Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA)(2003)138 cited
- → A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients(2011)133 cited